USPTO serial 86868672
HYPROXCYN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CHANG, KATHERINE S
- Law office
- TMO LAW OFFICE 115 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with HYPROXCYN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
New York City, NY
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dax D. Anderson
DAX D. ANDERSON Kirton McConkie60 E South Temple Ste 1800Salt Lake City, UT 84111-1032UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | personal lubricants, moisturizers, pharmaceuticals, pharmaceutical preparations, microbicides and drugs for medical purposes for treatment and prevention of sexually transmitted infections, viral, fungal and bacterial disease, namely, bacterial vaginosis, Chlamydia, herpes simplex virus, human papilloma virus, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), human immunodeficiency virus (HIV), gonorrhea and syphilis; chemical and biological preparations, substances for treatment and prevention of bacterial vaginosis, Chlamydia, herpes simplex virus, human papilloma virus, hepatitis, human immunodeficiency virus (HIV), Acquired Immune Deficiency Syndrome (AIDS); reagents and compounds for medical purposes; polyvalent compounds, synthetic molecules and dendrimers for medical purposes for treatment and prevention of bacterial vaginosis, Chlamydia, herpes simplex virus, human papilloma virus, hepatitis, human immunodeficiency virus (HIV), Acquired Immune Deficiency Syndrome (AIDS); antimicrobial preparations, namely, microbicidal preparations in the nature of gels, foams, creams, films, solutions, suppositories, suspensions and lotions for vaginal, rectal and transdermal use for treatment and prevention of bacterial vaginosis, Chlamydia, herpes simplex virus, human papilloma virus, hepatitis, human immunodeficiency virus (HIV), herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE | — |
| 010 | Contraceptive apparatus, namely, intravaginal cervical barriers; prophylactic instruments for use to prevent pregnancy and disease, namely, condoms, diaphragms, and intrauterine devices treated with personal lubricants, moisturizers, pharmaceuticals, pharmaceutical preparations, microbicides and drugs for medical purposes for treatment and prevention of sexually transmitted infections, viral, fungal and bacterial disease, namely, bacterial vaginosis, Chlamydia, herpes simplex virus, human papilloma virus, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), human immunodeficiency virus (HIV), gonorrhea and syphilis; chemical and biological preparations, substances for treatment and prevention of bacterial vaginosis, Chlamydia, herpes simplex virus, human papilloma virus, hepatitis, human immunodeficiency virus (HIV), Acquired Immune Deficiency Syndrome (AIDS); reagents and compounds for medical purposes; polyvalent compounds, synthetic molecules and dendrimers for medical purposes for treatment and prevention of bacterial vaginosis, Chlamydia, herpes simplex virus, human papilloma virus, hepatitis, human immunodeficiency virus (HIV), Acquired Immune Deficiency Syndrome (AIDS); antimicrobial preparations, namely, microbicidal preparations in the nature of gels, foams, creams, films, solutions, suppositories, suspensions and lotions for vaginal, rectal and transdermal use for treatment and prevention of bacterial vaginosis, Chlamydia, herpes simplex virus, human papilloma virus, hepatitis, human immunodeficiency virus (HIV), herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 5, 2017 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 5, 2017 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 7, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 31, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 25, 2016 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Apr 25, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 25, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 25, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 22, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 28, 2016 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jan 25, 2016 | ALIE | ASSIGNED TO LIE | — |
| Jan 15, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 11, 2016 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jan 11, 2016 | NWAP | NEW APPLICATION ENTERED | — |